Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-DXd for HER2-low or HER2 IHC0 metastatic breast cancer
NL-OMON60011Phase 2Active, not recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Sep 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trastuzumab deruxtecan in breast cancer (4 cohorts), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoint: Time to next treatment. Started Sep 2024; status: active, not recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
breast cancer
Beyond the preview
Go deeper on NL-OMON60011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60011.